Top 5 Pharma Stocks with high EBITDA margin

Q2 FY24

Concord Biotech Ltd.

Revenue ₹ 262 Cr EBITDA Margin 45.4%

Natco Pharma Ltd.

Revenue ₹ 1031 Cr EBITDA Margin 44.4%

Suven Pharma Ltd.

Revenue ₹ 231 Cr EBITDA Margin 42.4%

Eris Lifesciences Ltd.

Revenue ₹ 505 Cr EBITDA Margin 35.9%

Caplin Point Ltd.

Revenue ₹ 410 Cr EBITDA Margin 33.5%

Find out how the top pharma stocks performed since previous quarter!